• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Do Low Lipid Levels Increase Risk of Hemorrhagic Stroke in Women?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Previous studies have observed an inverse relationship between low-density lipoprotein cholesterol (LDL-C) levels and the risk of hemorrhagic stroke
  • Rist et al. (Neurology, 2019) examined the association between lipid levels and risk of hemorrhagic stroke among women

METHODS:

  • Prospective cohort study
  • Participants derived from Women’s Health Study (WHS)
    • RCT of low-dose aspirin and vitamin E for the primary prevention of cardiovascular disease (CVD) and cancer
    • 39,876 US female health professionals ≥45 years
    • Trial concluded in 2004 with ongoing follow-up
  • Measurements included
    • Total cholesterol
    • Low-density lipoprotein cholesterol (LDL-C)
    • High-density lipoprotein cholesterol (HDL-C)
    • Triglycerides
  • Strokes confirmed with medical records
  • Data analysis
    • Cox proportional hazards models to analyze associations between lipid categories and hemorrhagic stroke risk

RESULTS:

  • 27,937 women
    • Mean follow-up: 19.3 years
    • 137 hemorrhagic strokes
  • “U-shaped relationship between LDL-C and hemorrhagic stroke risk”
  • When compared to those with LDL-C levels 100-129.9 mg/dL, women with lowest LDL-C levels (<70 mg/dL ) were at significant risk of hemorrhagic stroke when adjusted for multiple confounders
    • Relative risk (RR): 2.17 (95% CI, 1.05-4.48)
  • There was no significant increase in risk of stroke in those with
    • LDL-C levels 130-159.9 mg/dL: RR 1.14 (95% CI, 0.72-1.80)
    • LDL-C levels 70-99.9 mg/dL: RR 1.25 (95% CI, 0.76-2.04)
  • There was a non-significant increase in risk for those with LDL-C levels ≥160 mg/dL
    • RR 1.53 (95% CI, 0.92-2.52)
  • Women with the lowest quartile of triglycerides had a significantly increased risk of hemorrhagic stroke compared to women in the top quartile after multivariable adjustment
    • RR 2.00 (95% CI, 1.18-3.39)
  • There were no significant associations between total cholesterol or HDL-C levels and hemorrhagic stroke risk

CONCLUSION:

  • Women with <70 mg/dL had 2.17 times the risk of hemorrhagic stroke compared to those with LDL-C levels 100-129.9 mg/dL
  • There may be benefit to identifying these individuals to help adjust modifiable risk factors such as BP and smoking
  • Further studies required to determine if there is additional risk for women with ≥160 mg/dL

Learn More – Primary Sources:

Lipid levels and the risk of hemorrhagic stroke among women

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ACC/AHA Blood Pressure Guideline: Current Classification System and Treatment Targets
Does Eating a Mediterranean Diet Reduce Risk of Stroke in Both Men and Women?
Do Artificially Sweetened Drinks Increase Risk for Stroke?
Cochrane Review: Do Omega-3 Fatty Acids Reduce Cardiovascular Disease? 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site